Clinical pharmacokinetics of amantadine hydrochloride
- PMID: 3280212
- DOI: 10.2165/00003088-198814010-00003
Clinical pharmacokinetics of amantadine hydrochloride
Abstract
Amantadine is a drug with diverse uses ranging from prevention of influenza A illness to the treatment of patients with Parkinson's disease. It is available only in oral formulations from which it is well absorbed and widely distributed, little drug being present in the circulation. Apparent volume of distribution is inversely related to dose over the therapeutic range and accounts in part for a noteworthy logarithmic increase in plasma concentration as a function of dose. Elimination is primarily by renal clearance by both glomerular filtration and tubular secretion. Amantadine accumulates in patients with renal dysfunction. Hence, doses must be reduced in such patients to avoid toxicity. Interactions with other drugs appear uncommon. Relationships have been demonstrated between amantadine therapeutic effects and plasma concentrations in different study cohorts, but not in individual patients. Dose schedules have been suggested for individuals in whom amantadine kinetics are different from healthy subjects. However, these schedules are controversial in their choice of target concentrations and in being untested as to predictive value.
Similar articles
-
Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets.CNS Drugs. 2019 Aug;33(8):783-789. doi: 10.1007/s40263-019-00651-1. CNS Drugs. 2019. PMID: 31342404 Free PMC article.
-
Amantadine hydrochloride: current and new uses.J Neurosci Nurs. 1990 Oct;22(5):322-5. doi: 10.1097/01376517-199010000-00011. J Neurosci Nurs. 1990. PMID: 2146341 Review. No abstract available.
-
Amantadine kinetics in healthy elderly men: implications for influenza prevention.Clin Pharmacol Ther. 1985 Feb;37(2):137-44. doi: 10.1038/clpt.1985.25. Clin Pharmacol Ther. 1985. PMID: 3967456
-
An amantadine hydrochloride dosing program adjusted for renal function during an influenza outbreak in elderly institutionalized patients.Can J Clin Pharmacol. 2003 Fall;10(3):119-22. Can J Clin Pharmacol. 2003. PMID: 14506511 Clinical Trial.
-
Rimantadine: a clinical perspective.Ann Pharmacother. 1995 Mar;29(3):299-310. doi: 10.1177/106002809502900312. Ann Pharmacother. 1995. PMID: 7606077 Review.
Cited by
-
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.J Neural Transm (Vienna). 2018 Aug;125(8):1237-1250. doi: 10.1007/s00702-018-1869-1. Epub 2018 Mar 7. J Neural Transm (Vienna). 2018. PMID: 29511826 Review.
-
Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager.Nat Biomed Eng. 2024 May;8(5):513-528. doi: 10.1038/s41551-023-01147-6. Epub 2024 Feb 20. Nat Biomed Eng. 2024. PMID: 38378820
-
Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets.CNS Drugs. 2019 Aug;33(8):783-789. doi: 10.1007/s40263-019-00651-1. CNS Drugs. 2019. PMID: 31342404 Free PMC article.
-
Amantadine-Induced Craniofacial Myoclonus: Distinctive Iatrogenic Dysarthria in Parkinson's Disease.Mov Disord Clin Pract. 2023 Jul 14;10(9):1408-1413. doi: 10.1002/mdc3.13828. eCollection 2023 Sep. Mov Disord Clin Pract. 2023. PMID: 37772280 Free PMC article. Review.
-
Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine.J Pharmacol Exp Ther. 2020 Jun;373(3):488-501. doi: 10.1124/jpet.120.264994. Epub 2020 Mar 20. J Pharmacol Exp Ther. 2020. PMID: 32198137 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical